Aquestive Therapeutics (AQST) Receivables - Net (2017 - 2025)
Historic Receivables - Net for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $11.8 million.
- Aquestive Therapeutics' Receivables - Net rose 2186.08% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 2186.08%. This contributed to the annual value of $7.3 million for FY2024, which is 1330.42% down from last year.
- Aquestive Therapeutics' Receivables - Net amounted to $11.8 million in Q3 2025, which was up 2186.08% from $11.9 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Receivables - Net ranged from a high of $19.9 million in Q1 2022 and a low of $4.7 million during Q4 2022
- Over the past 5 years, Aquestive Therapeutics' median Receivables - Net value was $10.2 million (recorded in 2021), while the average stood at $10.7 million.
- In the last 5 years, Aquestive Therapeutics' Receivables - Net tumbled by 6204.76% in 2023 and then soared by 9779.93% in 2025.
- Aquestive Therapeutics' Receivables - Net (Quarter) stood at $12.1 million in 2021, then plummeted by 61.19% to $4.7 million in 2022, then soared by 80.08% to $8.5 million in 2023, then dropped by 13.3% to $7.3 million in 2024, then skyrocketed by 60.69% to $11.8 million in 2025.
- Its last three reported values are $11.8 million in Q3 2025, $11.9 million for Q2 2025, and $10.4 million during Q1 2025.